Trials / Completed
CompletedNCT05177042
Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
A Phase 1b Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-110 in Combination With Abiraterone in Patients With Metastatic Prostate Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Arvinas Androgen Receptor, Inc. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase 1b study to assess the combination of ARV-110 and abiraterone in patients with metastatic prostate cancer with rising PSA values on abiraterone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARV-110 in Combination with Abiraterone | ARV-110 oral tablets in combination with abiraterone and a corticosteroid administered daily in 28 day cycles |
Timeline
- Start date
- 2022-02-01
- Primary completion
- 2024-07-02
- Completion
- 2025-04-10
- First posted
- 2022-01-04
- Last updated
- 2025-07-25
Locations
18 sites across 4 countries: United States, Canada, France, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05177042. Inclusion in this directory is not an endorsement.